Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 1/20 | 0.39 |
| ▸ | FDPS | P14324 | 6/20 | 0.38 |
| ▸ | LPAR3 | Q9UBY5 | 4/20 | 0.34 |
| ▸ | GGPS1 | O95749 | 3/20 | 0.34 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.34 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.34 |
| ▸ | SMPD1 | P17405 | 2/20 | 0.34 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.33 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11636720 | 0.85 | FDPS (0.39) | FDPSGGPS1SMPD1 | |
| SCHEMBL11173438 | 0.84 | LPAR3 (0.38) | PPARDFDPSLPAR3LPAR1LPAR2 | |
| SCHEMBL10924308 | 0.83 | PPARD (0.36) | PPARDFDPSLPAR3GGPS1LPAR1 | |
| SCHEMBL3741739 | 0.80 | FDPS (0.44) | FDPSLPAR3GGPS1LPAR1LPAR2 | |
| SCHEMBL1549416 | 0.78 | PPARD (0.47) | PPARD | |
| SCHEMBL11761619 | 0.76 | LPAR3 (0.44) | FDPSLPAR3GGPS1LPAR1LPAR2 | |
| SCHEMBL961898 | 0.76 | FDPS (0.36) | FDPSGGPS1SMPD1CYP4F2CYP4A11 | |
| SCHEMBL10682984 | 0.75 | FDPS (0.47) | FDPSLPAR3GGPS1LPAR1LPAR2 | |
| SCHEMBL16841368 | 0.75 | FDPS (0.35) | FDPSGGPS1SMPD1CYP4F2CYP4A11 | |
| SCHEMBL9732184 | 0.74 | PPARD (0.37) | PPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080058375-A1 | Bone disorders; osteoporosis; antihistamines; sexual disorders; antiinflammatory agents; antiarthritic agents; vision defects; antiulcer agents | ELWORTHY TODD R | 2008-03-06 | — | — | US | disclosed |
| US-7271183-B2 | 2-Piperidone derivatives as prostaglandin agonists | ROCHE PALO ALTO LLC (US) | 2007-09-18 | — | — | US | disclosed |
| EP-1585729-A1 | 2-PIPERIDONE DERIVATIVES AS PROSTAGLANDIN AGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2005-10-19 | — | — | EP | disclosed |
| WO-2004063158-A1 | 2-PIPERIDONE DERIVATIVES AS PROSTAGLANDIN AGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2004-07-29 | — | — | WO | disclosed |
| US-20040142969-A1 | 2-Piperidone derivatives as prostaglandin agonists | ROCHE PALO ALTO LLC | 2004-07-22 | — | — | US | disclosed |
| US-4983629-A | 11-haloprostane derivatives, processes for their preparation and their use as medicinal agents | SCHERING AKTIENGESELLSCHAFT (DE) | 1991-01-08 | — | — | US | disclosed |
| US-4806668-A | Process for the production of 9beta-chloroprostaglandins | SCHERING AKTIENGESELLSCHAFT (DE) | 1989-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058375-A1 | Bone disorders; osteoporosis; antihistamines; sexual disorders; antiinflammatory agents; antiarthritic agents; vision defects; antiulcer agents | C3AR1, C1R, HRH4 | PPARD 2701/4885FDPS 2628/4885LPAR3 396/4885 |
| US-20040142969-A1 | 2-Piperidone derivatives as prostaglandin agonists | PTGER1, PTGER2, PTGER4 | PPARD 287/4885FDPS 1593/4885LPAR3 101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.